Clinical trial · Interventional
Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma
Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma: an Open-label, Randomised, Prospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to determine the effectiveness of prophylactic antibiotic use for TACE and occurrence of postoperative liver abscess. There would be two comparison groups. Current standard of care treatment at PKLI\&RC (as per local guidelines) would be given to all patients receiving TACE for the intervention group or 'antibiotic group' (i.e., Inj. Ceftriaxone 1g, intravenous × stat). While no antibiotic would be given to the 'no antibiotic group'.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Antibiotic Prophylaxis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ceftriaxone Sodium | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- No Antibiotic Prophylaxis Group
- description
- No antibiotic will be administered prophylactically for TACE.
- type
- EXPERIMENTAL
- label
- Antibiotic Prophylaxis Group
- description
- Antibiotic will be administered prophylactically (i.e., Inj. Ceftriaxone 1g, intravenous × stat)
- interventionNames
- Drug: Ceftriaxone Sodium
Primary outcomes (3)
- measure
- Leukocytosis
- timeFrame
- 2 days
- description
- Predominantly neutrophilic leukocytosis ( \> 11 ×109/L) with fever ( \> 38 °C) in upto 48 hours post-TACE
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. Diagnosis of primary liver cancer or hepatocellular carcinoma. 2. Patients receiving TACE in PKLI \& RC. 3. Patients giving informed consent. Exclusion Criteria: 1. Receiving two or more TACE during the same hospitalization 2. Use of any antibiotics other than the prophylactic antibiotic in 48hours prior to TACE 3. Known hypersensitivity to specified antibiotic used in the study 4. Incomplete or missing laboratory investigations and data 5. Taking Sorafenib before TACE 6. TACE combined with ablation or immunetherapy 7. Tumor size \>10 cm 8. Portal vein thrombosis 9. Dilated biliary channels on CT scan / Billiary invasion by tumor
References
Publications (0)
Data not yet available